InsiderTrades.com logo
This is the worst sign for the U.S. stock market in 50 years
From Stansberry Research   |   Ad
The Dow recently posted its worst losing streak since 1974. And one of America's most accurate analysts now says this is just the beginning of a new crisis that could be worse than the COVID crash, the dot-com crash, and even the Great Depression. Introducing "The Dead Zone"
Click here to see Dan's new, urgent warning about the U.S. market for 2025.
Sung H. Lee net worth and biography
  • Phone
  • Email
  • Website

Sung Lee Biography and Net Worth

CFO & Member of Management Board of MorphoSys

Sung Lee came to MorphoSys in February 2021 and leads all corporate finance functions of the company. 

Sung Lee has more than 20 years of finance leadership experience in biopharmaceutical and technology businesses. He joined MorphoSys from Sangamo Therapeutics, Inc., where he served as Chief Financial Officer. Prior to that role, Mr. Lee spent nearly 14 years at Gilead Sciences where he most recently led the global Financial Planning & Analysis and Investor Relations functions. 

Lee started his career in the tax advisory business at PriceWaterhouseCoopers LLP. He received a Master of Business Taxation from the University of Southern California and a B.A. in Economics from the University of California, Irvine. 

How do I contact Sung H. Lee?

The corporate mailing address for Mr. Lee and other MorphoSys executives is SEMMELWEISSTR. 7, PLANEGG 2M, 82152. MorphoSys can also be reached via phone at (498) 989-9270 and via email at [email protected]. Learn More on Sung H. Lee's contact information.

Has Sung H. Lee been buying or selling shares of MorphoSys?

Sung H. Lee has not been actively trading shares of MorphoSys over the course of the past ninety days. Learn More on Sung H. Lee's trading history.

Who are MorphoSys' active insiders?

MorphoSys' insider roster includes Jean-Paul Kress (Chairman of Management Board), and Sung Lee (CFO & Member of Management Board ). Learn More on MorphoSys' active insiders.

Sung H. Lee Insider Trading History at MorphoSys

See Full Table

Sung H. Lee Buying and Selling Activity at MorphoSys

This chart shows Mr. Sung H. Lee's buying and selling at MorphoSys by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

MorphoSys Company Overview

MorphoSys logo
MorphoSys AG, together with its subsidiaries, engages in the development and commercialization of therapeutics for patients suffering from various cancers in Europe, Asia, and the United States. The company's product pipeline includes Pelabresib that is in Phase 3 trials to treat myelofibrosis and thrombocythemia; Tulmimetostat, a product candidate in Phase 1/2 trials for the treatment of solid tumors and lymphomas; Felzartamab, an antibody directed against CD38 for renal autoimmune diseases and relapsed/refractory multiple myeloma; Ianalumab, a candidate in Phase 3 clinical trials for Sjögren's disease, lupus nephritis, and other autoimmune diseases; Abelacimab that is in Phase 3 trials for venous thromboembolism prevention and cancer-associated thrombosis; Setrusumab, which is in Phase 2/3 trials for osteogenesis imperfecta; and Bimagrumab, a product candidate in Phase 2b trials for adult obesity. It also develops MOR210/TJ210/HIB210 that is in Phase 1 clinical trials for relapsed or refractory advanced solid tumors; and NOV-8, a candidate in Phase 2 trials for the treatment of pulmonary sarcoidosis and dermatitis. The company has collaboration and licensing agreements with I-Mab Biopharma, Novartis, Anthos Therapeutics, Ultragenyx, Mereo BioPharma, Lilly, Human Immunology Biosciences, Inc. Incyte Corporation, and Xencor, Inc. MorphoSys AG was founded in 1992 and is headquartered in Planegg, Germany.
Read More

Today's Range

Now: $18.96
Low: $18.96
High: $18.96

50 Day Range

MA: $18.96
Low: $18.96
High: $18.96

2 Week Range

Now: $18.96
Low: $4.18
High: $19.50

Volume

N/A

Average Volume

1,019,393 shs

Market Capitalization

$2.86 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.2
This is the worst sign for the U.S. stock market in 50 years
From Stansberry Research   |   Ad
The Dow recently posted its worst losing streak since 1974. And one of America's most accurate analysts now says this is just the beginning of a new crisis that could be worse than the COVID crash, the dot-com crash, and even the Great Depression. Introducing "The Dead Zone"
Click here to see Dan's new, urgent warning about the U.S. market for 2025.